Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round

By March 24, 2020 March 25th, 2020 Press Releases

MENLO PARK, Calif., March 24, 2020 /PRNewswire/ — Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing (AST) for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round.

The current investment round will allow Avails Medical to accelerate the development of its AST product pipeline, including the eQuant system, which was announced at ECCMID 2019. eQuant automates and closes the 24 hour workflow gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour. The McFarland standard is required in any conventional AST to ensure accurate results.

“As a leader in automation and healthcare, we are excited to join Avails in the fight against antibiotic resistance. Their revolutionary approach will transform hospital lab workflow and bring it to the 21st century, allowing hospitals to turn their outdated system into rapid ones overnight”, said Tomoko Inoue, CEO of OMRON VENTURES.

“OMRON’s mission to improve lives and contribute to a better society is aligned with Avails’ focus to fight the biggest global health threat – antibiotic resistance,” said Oren Knopfmacher, PhD, CEO and co-founder of Avails Medical. “This collaboration will allow Avails to learn from a true medical visionary and healthcare market leader, and together, collaboratively fight back against the rapid spread of antibiotic resistance.”

About Avails Medical
Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today’s biggest global health threats – antibiotic resistance. Founded by a team of Stanford University alums, the Avails technology platform is designed to significantly reduce the amount of time required to obtain the reliable antibiotic susceptibility data required to enable accurate therapy decisions.  Avails’ electronic biosensor technology is designed to improve accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps.

CONTACT: press@availsmedical.com

About OMRON VENTURES
OMRON VENTURES is the venture capital arm of OMRON Corporation and its affiliated companies. Its mission is to create a new world by joining hands with entrepreneurs all over the globe who see things in their own free way, who are unencumbered by conventional practice, and who seriously believe they can change the world. For more information, visit https://www.omron.com/ventures/

SOURCE Avails Medical, Inc.